Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis

被引:6
|
作者
Norambuena, X. [1 ]
Mallol, J. [2 ]
Rios, G. [1 ]
Quevedo, F. [3 ]
Quezada, A. [1 ,4 ]
机构
[1] Univ Santiago, Sch Med, Hosp Dr Exequiel Gonzalez Cortes, Pediat Unit, Santiago, Chile
[2] Univ Santiago, Sch Med, Dept Pediat Respiratory Med, Hosp CRS El Pino, Santiago, Chile
[3] Univ Chile, Sch Med, Educ Div Hlth Sci, Santiago, Chile
[4] Univ Chile, Sch Med, Dept Pediat, Santiago, Chile
关键词
juvenile idiopathic arthritis; infliximab; juvenile rheumatoid arthritis; RHEUMATOID-ARTHRITIS; FACTOR-ALPHA; PRELIMINARY DEFINITION; OPEN-LABEL; METHOTREXATE; IMPROVEMENT; ETANERCEPT;
D O I
10.1157/13101338
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Objective: To report the results of treatment with infliximab in patients with refractory juvenile idiopathic arthritis QIA). Patients and methods:A prospective study of four children with refractory JIA was carried out. Infliximab (1100 mg) was administered in weeks 0, 2 and 6. Subsequently, the drug was administered every 8 weeks. The following parameters were assessed at the beginning and at the end of the follow-up period: number of joints with active arthritis, number of joints with a limited range of motion, physician overall assessment of disease activity, parent assessment of the child's overall well-being, pain assessment scores, and erythrocyte sedimentation rate. Improvement was rated according to the definition of the American College of Rheumatology (ACR 30). Paired sample tests were used for statistical analysis. Results: Three girls and one boy aged between 10 and 16 years old with a history of JIA ranging from 1 to 9 years were included. The patients received infliximab for a period of 11 to 33 months (average 22 months). There was a significant decrease in the number of swollen joints (p < 0.05), joints with a limited range of movement (p < 0.04), pain score assessment (p < 0.005), physician overall assessment (p = 0.002), maternal evaluation (p < 0.001), the patient's own evaluation (p < 0.001), and duration of morning stiffness (p < 0.001). Both steroids and methotrexate dosages were reduced and no adverse effects or infections were registered. Conclusions: Infliximab improved joint inflammatory indexes and clinical assessments. This improvement increased the quality of life of the patients and their families, suggesting that the use of biological therapy is a good option in refractory JIA.
引用
收藏
页码:52 / 56
页数:5
相关论文
共 50 条
  • [21] Anti-tumor necrosis factor-alpha therapy with the chimeric monoclonal antibody infliximab in severe undifferentiated spondyloarthropathy
    Schnarr, S
    Huelsemann, JL
    Merkesdal, S
    Brandt, J
    Braun, J
    Prudlo-Winkler, S
    Zeidler, H
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 422 - 422
  • [22] A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor α agents
    Lurati, A.
    Pontikaki, I.
    Teruzzi, B.
    Desiati, F.
    Gerloni, V.
    Gattinara, M.
    Cimaz, R.
    Fantini, F.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1602 - 1607
  • [23] Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-α therapy -: Reply
    Kaur, PP
    Derk, CT
    Chatterji, M
    Dehoratius, RJ
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (04) : 826 - 827
  • [24] Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?
    Kai Liang Teh
    Lena Das
    Yun Xin Book
    Sook Fun Hoh
    Xiaocong Gao
    Thaschawee Arkachaisri
    Clinical Rheumatology, 2024, 43 : 1723 - 1733
  • [25] Ghrelin levels in patients with juvenile idiopathic arthritis: relation to anti-tumor necrosis factor treatment and disease activity
    Karagiozoglou-Lampoudi, Thomais
    Trachana, Maria
    Agakidis, Charalampos
    Pratsidou-Gertsi, Polyxeni
    Taparkou, Anna
    Lampoudi, Sotiria
    Kanakoudi-Tsakalidou, Florentia
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (10): : 1359 - 1362
  • [26] Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?
    Teh, Kai Liang
    Das, Lena
    Book, Yun Xin
    Hoh, Sook Fun
    Gao, Xiaocong
    Arkachaisri, Thaschawee
    CLINICAL RHEUMATOLOGY, 2024, 43 (05) : 1723 - 1733
  • [27] Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-α monoclonal antibody infliximab
    Brandt, J
    Haibel, H
    Reddig, J
    Sieper, J
    Braun, J
    JOURNAL OF RHEUMATOLOGY, 2002, 29 (01) : 118 - 122
  • [28] Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease
    Zaccagna, A
    Bertone, A
    Puiatti, P
    Picciotto, F
    Sprujevnik, T
    Santucci, R
    Rossini, FP
    EUROPEAN JOURNAL OF DERMATOLOGY, 2003, 13 (03) : 258 - 260
  • [29] Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab
    Tatò, F
    Rieger, J
    Hoffmann, U
    INTERNATIONAL ANGIOLOGY, 2005, 24 (03) : 304 - 307
  • [30] Pharmacokinetics and pharmacodynamics of infliximab, an anti-tumor necrosis factor-alpha monoclonal antibody, following single subcutaneous administrations in rheumatoid arthritis patients.
    Zhu, YW
    Pendley, C
    Sisco, D
    Westhovens, R
    Durez, P
    Bouman-Thio, E
    van Hartingsveldt, B
    Everitt, DE
    Graham, MA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P43 - P43